TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 200 μg QD
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 400 μg QD
Study: 36243386
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) therapeutic range (800 μg/day)
Study: 36243386
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) therapeutic range (1000 μg/day)
Study: 36243386
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) >3-fold above therapeutic dose range (644 μg/day)
Study: 33928435
Drug: Compression-only therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression-only therapy (CT) in a supine position
Study: 33753319
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided Erector Spinae Plane Block (ESPB) with 30 mL of 0.375% ropivacaine on each side
Study: 33753319
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (postoperative muscular infiltration with 30 mL of 0.75% ropivacaine)
Study: 85119806
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for Schistosoma haematobium infection
Study: 32912103
Drug: Analgesic medication
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medication on most days
Study: 32912103
Drug: Interference with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interference with daily activities
Study: 32467522
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac (60 mg/2 ml)
Study: 35427803
Drug: Monthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly intravitreal ranibizumab 0.5‐mg injections
Study: 35427803
Drug: PDS 100‐mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDS 100‐mg/ml vs Monthly ranibizumab
Study: 33764642
Drug: PO‐001 (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO‐001 (sustained-release cysteamine bitartrate) 600 mg
Study: 33764642
Drug: Cystagon® (immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystagon® (immediate-release cysteamine)
Study: 33764642
Drug: Procysbi® (delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procysbi® (delayed-release cysteamine)
Study: 32102263
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BJ) 70 mL
Study: 32957340
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose ketamine
Study: 38358703
Drug: Present-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present-centered therapy (PCT)
Study: 32307932
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of low-level laser therapy (LLLT) 1 hour before the insertion of elastomeric separators
Study: 32307932
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of low-level laser therapy (LLLT) 1 hour before and immediately after the insertion of elastomeric separators
Study: 35678643
Drug: Community children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community children (CC)
Study: 34119067
Drug: Pembrolizumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab alone or with chemotherapy
Study: 32424361
Drug: Therapeutic administration
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic administration of a single amino acid to experimentally infected mice
Study: 33993746
Drug: Daily rating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rating strategy
Study: 34611052
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg/kg of body mass
Study: 32819465
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with riociguat (MED group)
Study: 36336248
Drug: Centrally-administered system-wide
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally-administered system-wide implementation + local-tailored implementation
Study: 36336248
Drug: Centrally-administered system-wide
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally-administered system-wide implementation only
Study: 34837418
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablet of mosapride 5 mg, pancreatin 170 mg, and simethicone 125 mg
Study: 34837418
Drug: Single-component mosapride
Normalized name: mosapride
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-component mosapride tablets (reference product)
Study: 33110044
Drug: Fennel seed
Normalized name: FENNEL SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel seed powder (2 gr, four capsules daily for 8 weeks)
Study: 33110044
Drug: Starch-containing capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch-containing capsules (2 gr, four capsules daily for 8 weeks)
Study: 36434348
Drug: Immediate implants
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implants (type 1)
Study: 36434348
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants (type 4)
Study: 32700956
Drug: Light Therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light Therapy (LT)
Study: 32484623
Drug: 1% colloidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% colloidal oat eczema cream
Study: 34510141
Drug: Synthetic CBD
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic CBD 20 to 30 mg daily for 12 weeks
Study: 33939897
Drug: l-carnitine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine (50 mg/kg/day, twice a day for three months)
Study: 32111307
Drug: Montmorillonite (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorillonite (0.5 g/kg)
Study: 32111307
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis (5 × 10^8 cfu/kg) and Montmorillonite (0.5 g/kg) combination
Study: 33201054
Drug: Epithelial debridement,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epithelial debridement, aggressive lubrication, bandage contact lenses, reduction in chemotherapeutic dose to maintenance levels
Study: 35769693
Drug: Sublingual sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual sufentanil tablet (SST)
Study: 35769693
Drug: Standard-of-care (patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (patient-controlled epidural analgesia [PCEA] or PCA morphine)
Study: 33345583
Drug: Unified Protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders for Homeless Women (UPHW)
Study: 33512807
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk oligosaccharides (HMOs) - 5g daily dose of 2'‐fucosyllactose and lacto‐N‐neotetraose in a 4:1 mix
Study: 34773474
Drug: Erlotinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib + momelotinib (200 mg QD)
Study: 34773474
Drug: Erlotinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib + momelotinib (100 mg BID)
Study: 34773474
Drug: Erlotinib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib + momelotinib (various doses)
Study: 34088249
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health interventions focusing on depressive symptoms and behavior change skills (e.g., self-efficacy)
Study: 35672861
Drug: Preoperative inspiratory
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative inspiratory muscle training using Power®Breathe KHP2, 30 breaths twice a day for at least 2 weeks before surgery (can be extended up to 6 weeks).
Study: 35993772
Drug: In-hospital liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital liquid nitrogen therapy
Study: 35235197
Drug: Biofeedback +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback + fiber laxative (psyllium)
Study: 35235197
Drug: Biofeedback +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback + osmotic laxative (polyethylene glycol; PEG)
Study: 32179564
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioural therapy (iCBT) for Depression, available only in Finnish.
Study: 36205538
Drug: COBRA-light (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA-light (prednisolone 30 mg/day tapered to 7.5 mg/day, MTX increasing to 25 mg/week)
Study: 36205538
Drug: Intensification (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification (prednisolone 60 mg/day tapered to 7.5 mg/day, addition of SSZ (2 g/day) and HCQ (400 mg/day))
Study: 36205538
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy increasing to 25 mg/week
Study: 36205538
Drug: Intensification (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification (prednisolone 30 mg/day tapered to 7.5 mg/day)
Study: 35959775
Drug: Placebo (glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (glucose injection)
Study: 36170281
Drug: Minimal-flow: 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-flow: 0.25 l.min-1 via endotracheal tube
Study: 36170281
Drug: Low-flow: 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow: 2 l.min-1 + continuous jaw thrust
Study: 36170281
Drug: Medium-flow: 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-flow: 10 l.min-1 + continuous jaw thrust
Study: 36170281
Drug: High-flow: 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow: 70 l.min-1 + continuous jaw thrust
Study: 36170281
Drug: Control: 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: 70 l.min-1 + continuous video-laryngoscopy
Study: 35704597
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg, once daily)
Study: 616858603
Drug: Self-management intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management intervention along with conventional drug therapy
Study: 616858603
Drug: Standard outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard outpatient care and conventional drug therapy
Study: 35717855
Drug: Group-based Compassion-Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based Compassion-Focused Therapy (CFT)
Study: 36231747
Drug: Probiotic group
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic group (L. salivarius)
Study: 33207015
Drug: SQ tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ tree SLIT-tablet (containing birch extract)
Study: 32573396
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (light monotherapy)
Study: 32573396
Drug: Fluoxetine (fluoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (fluoxetine monotherapy)
Study: 35637038
Drug: Topical Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cannabidiol (CBD) 6.2 mg/mL with shea butter, applied twice daily for 2 weeks
Study: 35637038
Drug: Control: Shea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: Shea butter alone, applied twice daily for 2 weeks
Study: 32111479
Drug: Antioxidant formulation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant formulation (n = 85) containing 500 mg of vitamin C, 400 mg of vitamin E, 0.20 mg of selenium, 1,000 mg of l-carnitine, 20 mg of zinc, 1,000 μg of folic acid, 10 mg of lycopene daily
Study: 32111479
Drug: Antioxidant formulation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant formulation
Study: 34391309
Drug: Whole-Body Vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-Body Vibration (WBV) therapy, 12 sessions, amplitude of 3 mm, frequency of 20 Hz, 6 days/week for 2 weeks
Study: 32216204
Drug: Yishen Zhuangyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Zhuangyang Cream (YZC)
Study: 38874763
Drug: Reminiscence therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscence therapy
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model for pancreas segmentation at full dose CT
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model for pancreas segmentation at reduced dose CT
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model vs R1 at full dose CT
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model vs R2 at full dose CT
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model vs R1 at reduced dose CT
Study: 33595105
Drug: 3D CNN
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D CNN model vs R2 at reduced dose CT
Study: 34373322
Drug: Higher rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher rates of fluid infusion
Study: 32306925
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) in control wards.
Study: 36381249
Drug: Denosumab biosimilar
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab biosimilar (LY06006) 60 mg subcutaneously every 6 months for 1 year
Study: 33573699
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C (HDIVC) 6 g daily
Study: 34100922
Drug: Apremilast 20
Normalized name: apremilast 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 20 mg
Study: 32333486
Drug: Acceptance-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based group behavioral therapy (ABBT)
Study: 32333486
Drug: Standard nondirective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nondirective supportive group therapy (NDST)
Study: 36889873
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote monitoring data
Study: 32383227
Drug: Oral Nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nicotinamide (NAM) supplementation
Study: 34562564
Drug: Low-dose Guizhi
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Guizhi Fuling Wan
Study: 34562564
Drug: Conventional-dose Guizhi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose Guizhi Fuling Wan
Study: 34562564
Drug: Sub-effective dose
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-effective dose control (not explicitly named)
Study: 34434003
Drug: BMAC injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC injection followed by PRP injection
Study: 34434003
Drug: Gel-One® cross-linked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel-One® cross-linked hyaluronate (HA) injection
Study: 32445557
Drug: MG+SG (compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG+SG (compression with foam roller/ball + static stretching)
Study: 32445557
Drug: MG (compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG (compression only)
Study: 35049354
Drug: Automated insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated insulin delivery (AID)
Study: 34981778
Drug: Sustained oral
Normalized name: Sustain Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained oral peanut protein exposure
Study: 34981778
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of oral peanut protein exposure
Study: 32666822
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) for 24 months
Study: 34024878
Drug: Atorvastatin (statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (statin group)
Study: 35022147
Drug: Negative‐Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative‐Pressure Wound Therapy (NPWT)
Study: 32969513
Drug: Laplace-based algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laplace-based algorithm for treatment allocation
Study: 32035020
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus capivasertib (400 mg orally twice daily on an intermittent weekly schedule)
Study: 33798304
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with acupuncture at acupoints of limbs
Study: 33274895
Drug: Foliar application
Normalized name: Folicare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foliar application of algae at 8 g L‐1
Study: 33274895
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (foliar water)
Study: 34412973
Drug: HCG (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG (500 IU in 0.1 ml of tissue culture media)
Study: 34412973
Drug: Culture media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture media (0.1 ml of tissue culture media)
Study: 33400432
Drug: High-voltage PRF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage PRF combined with low-temperature CRF (70 V, 42°C, 2 Hz, pulse width 20 ms, treatment time 600 s; CRF at 60°C, treatment time 270 s)
Study: 33400432
Drug: High-voltage PRF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-voltage PRF only (70 V, 42°C, 2 Hz, pulse width 20 ms, treatment time 600 s)
Study: 32538008
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acupoint stimulation (TEAS) applied at specific acupoints on days 1, 2, 3, 5, 8, 14, 21, and 28 of chemotherapy, 30 minutes each time, once a day.
Study: 32538008
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group received DiyuShengbai tablets before chemotherapy, 2-3 tablets each time, 3 times a day.
Study: 32538008
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (chemotherapy with gemcitabine and cisplatin plus routine care)
Study: 33189857
Drug: tDCS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS with sham MCAT treatment
Study: 32571263
Drug: Individuals self-identifying
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals self-identifying as having or having had a prescription drug abuse issue
Study: 36336989
Drug: Reference product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (hydroxypropyl chitosan‐based 80 mg/g ciclopirox nail lacquer)
Study: 33567047
Drug: NPWT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPWT + PRP gel
Study: 32303260
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy program (10 two-hour weekly sessions)
Study: 33861679
Drug: Sabin inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabin inactivated poliovirus vaccine (sIPV)
Study: 33722384
Drug: Topical ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ivermectin 1% cream and placebo
Study: 35180260
Drug: Clown visits
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clown visits by RED NOSES Clowndoctors Austria on a weekly basis over four consecutive weeks
Study: 32542869
Drug: Transepidermal application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transepidermal application of CO2 (twice daily for 1 week)
Study: 32542869
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing hydrochloric acid (control)
Study: 35871338
Drug: Multimodal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal exercise program with omega-3 (900 mg EPA, 600 mg DHA), vitamin D (1000 IU), and protein (20 g) supplement (n=73)
Study: 35871338
Drug: Multimodal exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal exercise program with omega-3, vitamin D, and protein supplement (n=73)
Study: 38795716
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg every 4 weeks
Study: 33549192
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg every 8 weeks
Study: 33407609
Drug: Tomato sauce
Normalized name: Nutritional Supplement Oral Food, Solid [DIETARY SPECIALTIES TOMATO SAUCE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato sauce (OsteoCol) 150 ml/day